| Molecular formula | C149H246N44O42S |
|---|
| Molecular weight | 3357.9 g/mol |
|---|
| Registered trials | 42 |
|---|
| PubChem CID | 16132413 |
|---|
Regulatory Status
Sermorelin does not have an approved drug label in the data reviewed here. It is classified as an unapproved research compound, and the information below reflects registered clinical trial activity rather than any established medical use.
What Sermorelin Is
Sermorelin is a peptide with the molecular formula C149H246N44O42S and a molecular weight of approximately 3,357.9. Its structure corresponds to a chain of amino acids linked in a single sequence, consistent with a synthesized peptide fragment. No FDA-approved label, indication, or brand name is associated with this compound in the data reviewed.
Trial Footprint
Registered research on sermorelin spans 42 clinical trials. Sampled studies include a completed trial examining a growth hormone-releasing hormone antagonist's effect on growth hormone release in acromegaly, and a completed observational study following children with idiopathic growth hormone deficiency. Another sampled trial, completed and listed under an early research phase, investigated growth hormone releasing hormone's relationship to cognitive function in people with mild cognitive impairment. These entries describe study design and status only, not outcomes or established effects.
FAQ
No. Based on the data reviewed, sermorelin does not have an approved FDA label. It is currently studied only as a research compound, and no approved indication or brand name is on record here.
Sermorelin is a peptide compound made up of a defined amino acid sequence, with a molecular weight of about 3,357.9. It is chemically identified but does not carry an approved medical use in the data available.
Registered research includes 42 clinical trials. Sampled studies have looked at growth hormone release patterns and cognitive function, with statuses ranging to completed.
Examples in the available data include a completed trial on growth hormone-releasing hormone antagonism in acromegaly, an observational study in children with growth hormone deficiency, and an early-phase completed study on cognitive function in mild cognitive impairment. These describe study topics only, not results or proven effects.
No adverse event report data was available for sermorelin in this review, so no side effect pattern can be summarized here.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: ClinicalTrials.gov PubChem
Updated 2026-08-03